Comorbidity of schizophrenia and Parkinson’s disease: a clinical case report
Objective: To describe the case of a patient with paranoid schizophrenia followed by the onset of the Parkinson’s disease at the 44-year age Background: Currently…Safety of Pimavanserin for Parkinson’s Disease Psychosis: Exploratory Analysis of Sedation and Sleep Data From Clinical Studies
Objective: To summarize the sleep and sedation-related safety and tolerability of pimavanserin for the treatment of Parkinson’s disease psychosis (PDP). Background: Pimavanserin, a 5-HT2A receptor…Dopamine agonist use and psychotic symptoms in patients with Parkinson’s disease.
Objective: To describe the clinical and demographic characteristics of patients with PDP and their relationship with the use of DAs. Background: Parkinson’s Disease Psychosis (PDP)…Diagnostic Challenges in Functional Neurological Disorder: Convergent Psychogenic Non-Epileptic Seizures and Psychosis
Objective: To dissect the diagnostic challenges in distinguishing Functional Neurological Disorder (FND) coexisting with psychosis, highlighting the imperative for comprehensive and nuanced neuro-psychiatric assessment. Background:…Conceptualization of the MDS Parkinson’s Disease Psychosis Rating Scale (MDS-PDPRS) prototype.
Objective: To outline the process of conceptualizing the prototype for the International Parkinson and Movement Disorder Society Parkinson's Disease Psychosis Rating Scale (MDS-PDPRS). Background: Approximately…Pimavanserin Safety in Adult and Elderly Patients With Neuropsychiatric Symptoms Related to Neurodegenerative Disease: an Open-Label Extension Study
Objective: To assess the long-term safety and tolerability of pimavanserin in frail older adults and elderly patients with neuropsychiatric symptoms related to a neurodegenerative disease…Antipsychotic Prescriptions Among Nursing Home Residents with Parkinson’s Disease in the End-of-Life Period
Objective: To determine whether antipsychotic prescriptions differ between community-dwelling and nursing home residents with PD in the last 6 months of life. Background: Most antipsychotics…Development of an Item Bank for Assessing Psychosis in Parkinson’s Disease: A Systematic Review
Objective: This study aimed to develop an item bank for assessing psychosis in Parkinson's disease (PD). Background: Psychosis is a common and debilitating symptom in…Safety assessment of pimavanserin in Parkinson’s disease psychosis patients: Evidence from a systematic review and meta-analysis of randomized controlled trials
Objective: This systematic review and meta-analysis aimed to assess the safety profile of pimavanserin in Parkinson’s disease psychosis (PDP) patients from the available randomized controlled…Parkinson’s disease-associated psychosis in a Brazilian sample: worse cognitive outcomes, higher LEDD and longer disease duration.
Objective: To describe the prevalence of Parkinson's Disease (PD) associated psychosis (PDAP) at a Brazilian movement disorders outpatient and to evaluate its associated factors. Background:…
- 1
- 2
- 3
- …
- 12
- Next Page »